Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo

International Urology and Nephrology

Volumn 43, Issue 3, 2011, Pages 721-727

  Liu, Wanpeng ^a   Cao, Yanwei ^b   Fernández, Mario I ^c   Niu, Haitao ^b   Xiu, Youcheng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Bladder tumor; Chemotherapy; Gene therapy; Interleukin 12

Indexed keywords

INTERLEUKIN 12; PIRARUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER MORTALITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC RECOMBINATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOXORUBICIN; GENE THERAPY; HUMANS; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, ANIMAL; TRANSFECTION; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 80555139618     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9866-9     Document Type: Article

References (29)

1. Bolenz C, Cao Y, Fernández Arancibia M et al (2006) Intravesical mitomycin C for superficial transitional cell carcinoma. Expert Rev Anticancer Ther 6:1273-1282 (Pubitemid 44304695)
2. Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466-475 (Pubitemid 43259554)
3. Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 171:2186-2190 (Pubitemid 38625431)
4. Akagashi K, Tanda H, Kato S, Ohnishi S et al (2006) Recurrence pattern for superficial bladder cancer. Int J Urol 13(6):686-691 (Pubitemid 43926755)
5. O'Donnell MA, Luo Y, Hunter SE et al (2004) Interleukin-12 immunotherapy of murine transitional cell carcinoma ofthe bladder: Dose dependent tumor eradication and generation of protective immunity. J Urol 171:1330-1335 (Pubitemid 38327605)
6. Loskog AS, Fransson ME, Totterman TT (2005) AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 15:8816-8821 (Pubitemid 43005933)
7. Siemens DR, Austin JC, Hedican SP et al (2000) Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model. J Natl Cancer Inst 92: 403-412 (Pubitemid 30154822)
8. Chuang TF, Lee SC, Kw Liao et al (2009) Electroporationmediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 125:698-707
9. Carrion R, Seigne J (2002) Surgical management of bladder carcinoma. Cancer Control 9:284-292 (Pubitemid 34921034)
10. von der Maase H, Sengelov L, Roberts JT (2005) Longterm survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608 (Pubitemid 46224062)
11. Koya MP, Simon MA, Soloway MS (2006) Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175:2004-2010 (Pubitemid 43668507)
12. Manetti R, Parronchi P, Giudizi MG et al (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177:1104-1199
13. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146 (Pubitemid 37328691)
14. Colombo MP, Trinchieri G (2002) Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155-168
15. Gollob JA, Mier JW, Veenstra K et al (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-c induction is associated with clinical response. Clin Cancer Res 6:1678-1692 (Pubitemid 30305060)
16. Del Vecchio M, Bajetta E, Canova S et al (2007) Interleukin-12: Biological properties and clinical application. Clin Cancer Res 13:4677-4685 (Pubitemid 47294773)
17. Shiratori I, Suzuki Y, Oshiumi H et al (2007) Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model. Cancer Sci 98: 1936-19422
18. Teicher BA, Ara G, Buxton D et al (1997) Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 3:1661-1667 (Pubitemid 27431577)
19. Brunda MJ, Luistro L, Warrier RR et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumor. J Exp Med 197:1223-1230 (Pubitemid 23277355)
20. Weiss GR, O'Donnell MA, Loughlin K et al (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26:343-348 (Pubitemid 36858718)
21. Wang H, Yang G, Timme TL et al (2007) IL-12 genemodified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 14:819-827 (Pubitemid 47402378)
22. Horinaga M, Harsch KM, Fukuyama R et al (2005) Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 66:461-466 (Pubitemid 41138125)
23. Tan J, Newton CA, Djeu JY et al (1996) Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 56:3399-3403 (Pubitemid 26251626)
24. Tsai YS, Shiau AL, Chen YF et al (2010) Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: A promising strategy for bladder cancer therapy. Cancer Gene Ther 17:37-48
25. Zaharoff DA, Hoffman BS, Hooper HB et al (2009) Intravesical Immunotherapy of superficial bladder cancer with Chitosan/Interleukin-12. Cancer Res 69:6192-6199
26. Leist M, Jaattela M (2001) Triggering of apoptosis by cathepsins. Cell Death Differ 8:324-326 (Pubitemid 32409602)
27. Khan T, Hixon JA, Stauffer JK et al (2006) Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma. J Natl Cancer Inst 98:190-202 (Pubitemid 43205481)
28. Loeffler M, Kroemer G (2000) The mitochondrion in cell death control: Certainties and incognita. Exp Cell Res 256:19-26 (Pubitemid 30211162)
29. Kaufmann SH, Earnshwa WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49 (Pubitemid 30211165)